よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (89 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
16. Coyne AJK, et al. High-dose Cefepime vs Carbapenems for Bacteremia Caused by
Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase
Production. Open Forum Infect Dis. 2023. 10(3):ofad034.
4
5
6
17. Hareza D, et al. The Frequency of Extended-Spectrum β-Lactamase Genes Harbored
by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC
Expression. Open Forum Infect Dis. 2023. 10(4):ofad175.
7
8
18. Maan G, et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob
Chemother. 2022. 77(11):2908-2921.
9
10
11
12
13
19. Stewart AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment
of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp,
Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A
Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis.
2021. 8(8):ofab387.
14
15
16
20. Falagas ME, et al. Clinical outcomes with extended or continuous versus short-term
intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review
and meta-analysis. Clin Infect Dis. 2013. 56(2):272-282.
17
18
19
21. Tamma PD, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued
Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA. Intern Med. 2019. 179(3):316-323.
20
21
22
22. Punjabi C, et al. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ss-lactams
as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and
Meta-analysis. Open Forum Infect Dis. 2019. 6(10):ofz364.
23
24
25
23. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本
TDM 学会. 2022. at
https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
26
27
28
24. Vidal L, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and
meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007. 60(2):247257.
29
30
31
32
25. Castanheira M, et al. Activity of Plazomicin Tested against Enterobacterales Isolates
Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on
Susceptibility Rates among Aminoglycosides. Antimicrob Agents Chemother. 2020.
64(10):e02418-19.
33
34
35
36
26. Ikenoue C, et al. The importance of meropenem resistance, rather than imipenem
resistance, in defining carbapenem-resistant Enterobacterales for public health
surveillance: an analysis of national population-based surveillance. BMC Infect Dis.
2024. 15;24(1):209.
37
38
39
27. 厚生労働省. 健康・生活衛生局感染症対策部 感染症対策課. 5 類感染症に指定されている
薬剤耐性菌感染症の検討. 第 92 回厚生科学審査会感染症部会 資料 2. 2024 年 12 月 13
日. https://www.mhlw.go.jp/content/10906000/001352580.pdf
40
41
42
43
28. Saito S, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes
and Risk Factors of Patients with IMP-Type Carbapenemase-Producing CarbapenemResistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021.
65(3):e01483-20.
44
45
46
29. van Loon K, et al. A Systematic Review and Meta-analyses of the Clinical Epidemiology
of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017.
62(1):e01730-17.
89
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
16. Coyne AJK, et al. High-dose Cefepime vs Carbapenems for Bacteremia Caused by
Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase
Production. Open Forum Infect Dis. 2023. 10(3):ofad034.
4
5
6
17. Hareza D, et al. The Frequency of Extended-Spectrum β-Lactamase Genes Harbored
by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC
Expression. Open Forum Infect Dis. 2023. 10(4):ofad175.
7
8
18. Maan G, et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob
Chemother. 2022. 77(11):2908-2921.
9
10
11
12
13
19. Stewart AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment
of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp,
Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A
Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis.
2021. 8(8):ofab387.
14
15
16
20. Falagas ME, et al. Clinical outcomes with extended or continuous versus short-term
intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review
and meta-analysis. Clin Infect Dis. 2013. 56(2):272-282.
17
18
19
21. Tamma PD, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued
Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA. Intern Med. 2019. 179(3):316-323.
20
21
22
22. Punjabi C, et al. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ss-lactams
as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and
Meta-analysis. Open Forum Infect Dis. 2019. 6(10):ofz364.
23
24
25
23. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本
TDM 学会. 2022. at
https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
26
27
28
24. Vidal L, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and
meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007. 60(2):247257.
29
30
31
32
25. Castanheira M, et al. Activity of Plazomicin Tested against Enterobacterales Isolates
Collected from U.S. Hospitals in 2016-2017: Effect of Different Breakpoint Criteria on
Susceptibility Rates among Aminoglycosides. Antimicrob Agents Chemother. 2020.
64(10):e02418-19.
33
34
35
36
26. Ikenoue C, et al. The importance of meropenem resistance, rather than imipenem
resistance, in defining carbapenem-resistant Enterobacterales for public health
surveillance: an analysis of national population-based surveillance. BMC Infect Dis.
2024. 15;24(1):209.
37
38
39
27. 厚生労働省. 健康・生活衛生局感染症対策部 感染症対策課. 5 類感染症に指定されている
薬剤耐性菌感染症の検討. 第 92 回厚生科学審査会感染症部会 資料 2. 2024 年 12 月 13
日. https://www.mhlw.go.jp/content/10906000/001352580.pdf
40
41
42
43
28. Saito S, et al. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes
and Risk Factors of Patients with IMP-Type Carbapenemase-Producing CarbapenemResistant Enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021.
65(3):e01483-20.
44
45
46
29. van Loon K, et al. A Systematic Review and Meta-analyses of the Clinical Epidemiology
of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017.
62(1):e01730-17.
89